Manufacturers/Baxter Healthcare Corporation

Baxter Healthcare Corporation

35 drugs in NADAC|35 Generic,0 Brand

View Recalls (50)

Baxter Healthcare Corporation lists 35 NDCs in the CMS NADAC file (35 generic, 0 brand), at an average NADAC of $8.33 per unit, with a week-over-week move of -0.4% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.

Total Drugs

35

35G / 0B

Avg Price / Unit

$8.3325

$0.00 – $227.72

Avg 7d Change

-0.44%

Across 13 drugs with changes

7d Activity

6↑7↓22 flat

of 35 total drugs

Portfolio Price Trend

Monthly average NADAC price across all drugs

Keep following this manufacturer

These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.

Frequently Asked Questions

How many drugs does Baxter Healthcare Corporation make?

Baxter Healthcare Corporation lists 35 NDCs in the CMS NADAC file — 35 generic and 0 brand products.

What is the average price of Baxter Healthcare Corporation drugs?

The average NADAC across Baxter Healthcare Corporation's portfolio is $8.3325 per unit, ranging from $0.0009 to $227.7200.

What types of drugs does Baxter Healthcare Corporation make?

Baxter Healthcare Corporation makes drugs across 15 FDA pharmacologic classes. The most common by NDC count are Osmotic Laxative (20), Opioid Antagonist (3), Blood Coagulation Factor (3), Phosphate Binder (3), Potassium Salt (3).

Has Baxter Healthcare Corporation had any drug recalls?

50 FDA recalls are matched to Baxter Healthcare Corporation in the openFDA feed, most recently on Aug 17, 2026.

How has Baxter Healthcare Corporation's pricing changed recently?

Over the past 7 days, 6 Baxter Healthcare Corporation products rose and 7 fell, with a portfolio-wide average change of -0.4%.

Drug Portfolio

35 drugs total, 35 shown

Drug ↕Price 7d Change ↕
CYCLOPHOSPHAMIDE 500 MG VIAL
cyclophosphamide
$227.7200
per EA
—
FOSAPREPITANT 150 MG VIAL
Fosaprepitant Dimeglumine
$38.5080
per EA
—
NALOXONE 2 MG/2 ML SYRINGE
naloxone hydrochloride
$12.7410
per ML
-5.65%
NALOXONE 0.4 MG/ML VIAL
naloxone hydrochloride
$3.8243
per ML
-4.74%
NALOXONE 4 MG/10 ML VIAL
NALOXONE HYDROCHLORIDE
$3.8243
per ML
-4.74%
FLUMAZENIL 0.5 MG/5 ML VIAL
Flumazenil
$1.1791
per ML
—
KETOROLAC 30 MG/ML VIAL
ketorolac tromethamine
$1.0175
per ML
-2.61%
TOBRAMYCIN 80 MG/2 ML VIAL
Tobramycin
$0.8315
per ML
+12.45%
FUROSEMIDE 20 MG/2 ML VIAL
furosemide
$0.4901
per ML
+6.18%
TRANEXAMIC ACID 1,000 MG/10 ML
tranexamic acid
$0.4035
per ML
+4.32%
ROCURONIUM 50 MG/5 ML VIAL
Rocuronium Bromide
$0.3942
per ML
—
FUROSEMIDE 40 MG/4 ML VIAL
furosemide
$0.2525
per ML
-4.99%
LABETALOL HCL 100 MG/20 ML VL
Labetalol Hydrochloride
$0.1852
per ML
-8.29%
ONDANSETRON HCL 4 MG/2 ML VIAL
ONDANSETRON HYDROCHLORIDE
$0.1759
per ML
-0.69%
SODIUM CHLORIDE 0.9% SOLUTION
Sodium Chloride
$0.0198
per ML
—
SODIUM CHLORIDE 0.9% SOLUTION
Sodium Chloride
$0.0198
per ML
—
SODIUM CHLORIDE 0.9% SOLUTION
Sodium Chloride
$0.0062
per ML
—
SODIUM CHLORIDE 0.9% SOLUTION
Sodium Chloride
$0.0043
per ML
—
LACTATED RINGERS 1,000 ML
Sodium chloride, potassium chloride, sodium lactate and calcium chloride
$0.0038
per ML
+1.05%
LACTATED RINGERS INJECTION
Sodium chloride, potassium chloride, sodium lactate and calcium chloride
$0.0038
per ML
+1.05%
SODIUM CHLORIDE 0.9% IRRIG.
sodium chloride
$0.0035
per ML
—
ACETIC ACID 0.25% IRRIG SOLN
Acetic Acid
$0.0030
per ML
—
DEXTROSE 5%-WATER IV SOLN
DEXTROSE MONOHYDRATE
$0.0027
per ML
—
DEXTROSE 5%-WATER IV SOLN
DEXTROSE MONOHYDRATE
$0.0027
per ML
—
STERILE WATER FOR INJECTION
Water
$0.0021
per ML
—
STERILE WATER FOR INJECTION
Water
$0.0021
per ML
—
STERILE WATER FOR INJECTION
Water
$0.0021
per ML
—
SODIUM CHLORIDE 0.9% SOLUTION
Sodium Chloride
$0.0021
per ML
+0.97%
LACTATED RINGERS INJECTION
Sodium chloride, potassium chloride, sodium lactate and calcium chloride
$0.0020
per ML
—
SODIUM CHLORIDE 0.45% SOLN
Sodium Chloride
$0.0019
per ML
—
DEXTROSE 5%-0.45% NACL IV SOLN
Dextrose and Sodium Chloride
$0.0015
per ML
—
DEXTROSE 5%-0.45% NACL IV SOLN
Dextrose and Sodium Chloride
$0.0015
per ML
—
SODIUM CHLORIDE 0.9% IRRIG.
Sodium Chloride
$0.0014
per ML
—
SODIUM CHLORIDE 0.9% IRRIG.
sodium chloride
$0.0014
per ML
—
STERILE WATER FOR IRRIGATION
Water
$0.0009
per ML
—

FDA Recalls (50)

Recalls matched by company name. Verify current status with FDA.

D-0850-2026 →
Ongoing
Class I

Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL, 60016, Made in USA, NDC 00338-0719-06

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Initiated: 8/17/2026
D-0849-2026 →
Ongoing
Class I

0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 units per case. Baxter Healthcare Corporation, Deerfield, IL, 60015, USA, Made in USA, NDC 0338-0049-03

Presence of particulate matter: Particulates identified as fiberglass

Initiated: 8/17/2026
D-0816-2026 →
Ongoing
Class II

Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50.

CGMP Deviations

Initiated: 8/6/2026
D-0812-2026 →
Ongoing
Class II

Pantoprazole Sodium in 0.9% Sodium Chloride Injection, 80 mg/100 mL (0.8 mg/mL) Single-Dose Infusion Bag in 100 mL GALAXY Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60015, USA, NDC 0338-9648-12.

CGMP Deviations

Initiated: 8/6/2026
D-0806-2026 →
Ongoing
Class II

MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.

CGMP Deviations

Initiated: 8/6/2026
D-0807-2026 →
Ongoing
Class II

Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose Container (24 bags/carton), Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0714-24.

CGMP Deviations

Initiated: 8/6/2026
D-0813-2026 →
Ongoing
Class II

CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.

CGMP Deviations

Initiated: 8/6/2026
D-0815-2026 →
Ongoing
Class II

Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50.

CGMP Deviations

Initiated: 8/6/2026
D-0805-2026 →
Ongoing
Class II

Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), in GALAXY Single-Dose Container, Rx only, Sterile Nonpyrogenic, Iso-osmotic, Baxter Healthcare Corporation, Deerfield, IL, 60015 USA, NDC 0338-3552-48.

CGMP Deviations

Initiated: 8/6/2026
D-0818-2026 →
Ongoing
Class II

Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-995-24.

CGMP Deviations

Initiated: 8/6/2026
D-0819-2026 →
Ongoing
Class II

Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60015 USA, NDC 0338-9647-12.

CGMP Deviations

Initiated: 8/6/2026
D-0820-2026 →
Ongoing
Class II

Vancomycin Injection, USP, in 0.9% Sodium Chloride, 1g per 200 mL (5 mg/mL) in GALAXY Single-Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL, 60015 USA, NDC 0338-3583-01.

CGMP Deviations

Initiated: 8/6/2026
D-0809-2026 →
Ongoing
Class II

Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single Dose Container, Rx Only, Sterile Nonpyrogenic, Baxter International Inc., Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-5197-41.

CGMP Deviations

Initiated: 8/6/2026
D-0817-2026 →
Ongoing
Class II

Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-4114-50.

CGMP Deviations

Initiated: 8/6/2026
D-0811-2026 →
Ongoing
Class II

Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60012 USA, NDC 0338-9640-12.

CGMP Deviations

Initiated: 8/6/2026
D-0821-2026 →
Ongoing
Class II

Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1,000 mg total, in 1000 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0718-12.

CGMP Deviations

Initiated: 8/6/2026
D-0810-2026 →
Ongoing
Class II

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 400 mcg per 100 mL (4 mcg/mL) in Galaxy 100 mL Single Dose Container, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015, USA, NDC 0338-9557-12.

CGMP Deviations

Initiated: 8/6/2026
D-0808-2026 →
Ongoing
Class II

Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3612-50.

CGMP Deviations

Initiated: 8/6/2026
D-0814-2026 →
Ongoing
Class II

Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose Container, sterile, Nonpyrogenic, iso-osmotic solution in Dextrose, Baxter Healthcare Corporation, Deerfield, IL 60015, Made in the USA, NDC 43066-360-20.

CGMP Deviations

Initiated: 8/6/2026
D-0787-2026 →
Ongoing
Class I

Cefazolin in Dextrose, Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix, Sterile, Rx only, Manufactured by Baxter Healthcare Corporation, Deerfield, IL 60015, USA, NDC 0338-3508-41.

Presence of Particulate Matter

Initiated: 7/24/2026
D-0296-2026 →
Ongoing
Class II

Sterile Water for Irrigation, 250 mL, Single-Dose Plastic Bottle, Rx Only, Baxter Healthcare Corporation Deerfield, IL 60015 NDC: 0338-0004-02.

Presence of particulate matter: plastic particles from the bottle rim were observed floating into the solution

Initiated: 12/22/2025
D-0596-2025 →
Ongoing
Class II

Acetaminophen Injection 1000 mg/100 mL (10 mg/mL), packaged in 100 mL Viaflo container, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015, Made in Ireland, NDC 36000-306-60.

Discoloration

Initiated: 8/20/2025
D-0039-2025 →
Ongoing
Class II

Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL), 5mL Single-Dose Pre-filled Syringe, Rx only, Manufactured by: Baxter Pharmaceutical Solutions, LLC, Bloomington, IN 47403; Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC: 36000-364-01

Labeling: Missing Label

Initiated: 10/30/2024
D-0649-2024 →
Ongoing
Class I

Heparin (Heparin Sodium in 0.9% Sodium Chloride Injection), 2,000 units per 1,000 mL (2 units/mL), 1000 mL Sterile Single Dose Container, Rx Only, Baxter USA, NDC 0338-0433-04

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

Initiated: 8/1/2024
D-0587-2024 →
Ongoing
Class II

Dianeal Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose, For Intraperitoneal Administration Only, 6000 mL per bag, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA. NDC: 0941-0457-01

Lack of Assurance of Sterility: Potential presence of leaks originating from the Connector Assembly component.

Initiated: 6/17/2024
D-0336-2024 →
Ongoing
Class II

Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), For Intravenous Infusion Only, 250 mL vial, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015. Made in Ireland. NDC: 0338-0108-20

Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL.

Initiated: 1/23/2024
D-0146-2024 →
Completed
Class II

Ondansetron Injection, USP, 4 mg/2 mL (2 mg/mL), 2 mL per vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Manufactured by: Baxter Pharmaceuticals India Private Ltd, Ahmedabad 382213, India. NDC 36000-012-25

Failed pH Specifications

Initiated: 11/14/2023
D-0048-2024 →
Terminated
Class II

Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC 0338-0067-01

CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.

Initiated: 8/24/2023
D-1103-2023 →
Completed
Class III

Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01.

Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.

Initiated: 8/14/2023
D-1140-2023 →
Terminated
Class II

DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution 1.5% Dextrose, packaged in a) 2000 mL AMBU-FLEX II Container bag, Product Code L5B4825, NDC 0941-0409-06; b) 5000 mL AMBU-FLEX II Container bag, Product Code L5B4826, NDC 0941-0409-07; and c) 6000 mL AMBU-FLEX II Container bag, Product Code L5B9770, NDC 0941-0409-01, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA.

Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component.

Initiated: 8/11/2023
D-1141-2023 →
Terminated
Class II

Dianeal PD-2 Peritonial Dialysis Solution with 1.5% Dextrose, 5000 mL AMBU-FLEX ll Container with yellow pull ring, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA Product code L5B5193 NDC 0941-0411-07

Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component.

Initiated: 8/11/2023
D-0543-2023 →
Completed
Class II

Dianeal PD-2 Peritonial Dialysis Solution with 1.5% Dextrose, 3000 mL per Ambu-Flex II Container bag, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Product Code L5B5169, NDC 0941-0411-04.

Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component.

Initiated: 3/15/2023
D-0542-2023 →
Completed
Class II

Dianeal Low Calcium (2.5 mEq/L) Peritonial Dialysis Solution with 1.5% Dextrose, packaged in a) 5000 mL per Ambu-Flex II Container bag, Product Code L5B4826, NDC 0941-0409-07; and b) 6000 mL per Ambu-Flex II Container bag, Product Code L5B9770, NDC 0941-0409-01, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA.

Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component.

Initiated: 3/15/2023
D-1348-2022 →
Terminated
Class II

Acetaminophen Injection, 10 mg/mL, 1,000 mg/100 mL, 100 mL VIAFLO container bag, Single Dose Container, For Intravenous Use Only, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA; NDC 36000-306-60

Temperature Abuse: Product distributed in refrigerated trucks with labels attached to pallets indicating "Refrigerate Upon Arrival", however product is labeled to be stored in a controlled room temperature environment.

Initiated: 8/4/2022
D-0076-2021 →
Terminated
Class II

Bupivacaine Hydrochloride in 8.25% Dextrose Injection, USP Spinal 0.75% (15 mg/2 mL) 10 x 2 mL single-dose ampules, Rx only, Manufactured for: Baxter Healthcare Corporation Deerfield, IL 60015 USA, Manufactured by: Baxter Pharmaceuticals India Private Ltd Ahmedabad 382213 India, NDC 36000-092-10

Presence of particulate matter in solution - black and transparent particles

Initiated: 10/7/2020
D-0517-2020 →
Terminated
Class II

0.9% Sodium Chloride Irrigation USP 5000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL 60015, NDC 0338-0047-29

Lack of Assurance of Sterility: Product has the potential to leak.

Initiated: 11/19/2019
D-1514-2019 →
Terminated
Class II

0.9% Sodium Chloride Injection USP, 100 mL Viaflex Container, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015, USA, NDC 0338-0049-38.

Lack of Assurance of Sterility: Bags have potential to leak.

Initiated: 7/18/2019
D-1435-2019 →
Terminated
Class II

Sevoflurane, USP Inhalation Anesthetic 250 mL bottles, Rx only, Manufactured for Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 10019-651-64

Failed Stability Specifications

Initiated: 6/13/2019
D-0351-2019 →
Terminated
Class II

Dianeal Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 2000 mL UltraBag container bag, Rx only; Baxter Healthcare Corporation, Deerfield, IL 60015; Product Code 5B9766, NDC 0941-0424-52.

Lack of Assurance of Sterility: Confirmed customer complaints for leaks on the tubing.

Initiated: 1/2/2019
D-0222-2019 →
Terminated
Class III

Metoprolol Tartrate Injection, USP, 5 mg/ 5 mL (1 mg/mL), 5 mL per sterile single use glass vial, Rx Only, Manufactured for: Claris Lifesciences, Inc., North Brunswick, NJ 08902. By: Claris Injectables Ltd., Gujarat, India. NDC: 36000-033-10

Failed pH Specifications: Upward shift in the pH of the solution within the shelf life of the impacted lots.

Initiated: 10/15/2018
D-1215-2018 →
Terminated
Class III

Levofloxacin Injection in 5% Dextrose, 5 mg/mL, packaged in a) 50 mL (NDC 36000-046-24), b) 100 mL (NDC 36000-047-24), c) 150 mL (NDC 36000-048-24) Container bags, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India.

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

Initiated: 9/25/2018
D-1190-2018 →
Terminated
Class II

0.9% Sodium Chloride Injection USP 50 mL Viaflex container Baxter Healthcare Corporation Deerfield, IL 60015 -- NDC 0338-0049-31

cGMP Deviation

Initiated: 9/6/2018
D-1128-2018 →
Terminated
Class II

0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18

CGMP Deviations

Initiated: 8/21/2018
D-1035-2018 →
Terminated
Class III

Levofloxacin Injection in 5% Dextrose, 500 mg (5 mg/mL), 500 mg in 100 mL 5% Dextrose, 100 mL Single Use Container bag, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India, NDC 36000-047-24.

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

Initiated: 8/1/2018
D-1036-2018 →
Terminated
Class III

Levofloxacin Injection in 5% Dextrose, 750 mg (5 mg/mL), 750 mg in 150 mL 5% Dextrose, 150 mL Single Use Container bag, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India, NDC 36000-048-24.

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

Initiated: 8/1/2018
D-1034-2018 →
Terminated
Class III

Levofloxacin Injection in 5% Dextrose, 250 mg (5 mg/mL), 250 mg in 50 mL 5% Dextrose, 50 mL Single Use Container bag, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India, NDC 36000-046-24.

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

Initiated: 8/1/2018
D-0573-2018 →
Terminated
Class I

Nexterone (amiodarone HCl) Premixed Injection, 150mg/100mL, 100-mL bag, Rx Only, Sterile, Baxter Healthcare Corporation, Deerfield, IL. NDC 43066-150-10

Presence of Particulate Matter:Particulate identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which product is packaged

Initiated: 11/10/2017
D-0030-2018 →
Terminated
Class I

Intralipid 20%, A 20% I.V. Fat Emulsion, 100 ml bag, Rx only, Manufactured by Fresenius Kabi, Uppsala, Sweden for Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0519-58

Temperature Abuse: A portion of this product lot was exposed to subfreezing temperatures, which is outside of the acceptable storage range listed on the product labeling, during transit to a distribution facility.

Initiated: 9/15/2017
D-0973-2017 →
Terminated
Class II

0.9% Sodium Chloride Injection, USP, 100 mL VIAFLEX Container, Rx Only, Baxter Healthcare Corporation, Deerfield IL 60015 USA, Product Code: 2B1309, NDC: 0338-0049-38

Lack of Assurance of Sterility: Bags have the potential to leak.

Initiated: 7/6/2017
D-0957-2017 →
Terminated
Class II

0.9% Sodium Chloride Injection USP, 250 mL VIAFLEX Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015; Distributed in Canada by Baxter Corporation, Toronto, Ontario, Canada, Product Code: 2B1322, NDC 0338-0049-02.

Lack of Assurance of Sterility: Customer complaints for leaking bags.

Initiated: 7/6/2017